Melbourne, Victoria, Australia In 2007 was created Medical Research Commercialisation Fund (MRCF), which is appeared as VC. The main department of described VC is located in the Melbourne. The company was established in Australia.
The overall number of key employees were 1.
This Medical Research Commercialisation Fund (MRCF) works on 24 percentage points less the average amount of lead investments comparing to the other organizations. The increased amount of exits for fund were in 2014. The fund is generally included in less than 2 deals every year. The usual things for fund are deals in the range of 5 - 10 millions dollars. Speaking about the real fund results, this VC is 4 percentage points less often commits exit comparing to other organizations. The top activity for fund was in 2013. Despite it in 2019 the fund had an activity.
The fund has exact preference in some founders of portfolio startups. If startup sums 2 or 5+ of the founder, the chance for it to be financed is low. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - Australia. Among the most popular portfolio startups of the fund, we may highlight Paragen Bio, OncoRes Medical, OccuRx. Among the most popular fund investment industries, there are Biotechnology, Medical Device.
The typical case for the fund is to invest in rounds with 2-3 participants. Despite the Medical Research Commercialisation Fund (MRCF), startups are often financed by State Government of Victoria, Brandon Capital Partners. The meaningful sponsors for the fund in investment in the same round are Uniseed Ventures, OneVentures, Brandon Capital Partners. In the next rounds fund is usually obtained by Pitch@Palace, OneVentures, Imperial Innovations.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Aqua Fund | - |
| Bricklayers and Allied Craftworkers | Pennsylvania, Philadelphia, United States |
| Dutch Crypto Investors | - |
| France Telecom Technologies Investissements | France, Ile-de-France, Issy-les-moulineaux |
| Galleon Group | New York, New York, United States |
| GrubMarket | - |
| I2 Technologies | Dallas, Texas, United States |
| Incept | Ann Arbor, Michigan, United States |
| ItalBank International | Puerto Rico, San Juan, United States |
| Larkspur Capital Corporation | New York, New York, United States |
| Mana Impact | China, Hong Kong, Hong Kong Island |
| MUFG Union Bank | New York, New York, United States |
| Ryan Fund | Beijing, Beijing, China |
| SANAD Fund | Frankfurt, Germany, Hessen |
| Saturn Five | Austin, Texas, United States |
| SETOUCHI DMO | Hiroshima, Hiroshima Prefecture, Japan |
| Setouchi Kanko Kasseika Fund | - |
| Shenzhen Huanuo Innovation | China, Guangdong, Shenzhen |
| Z-kai | Japan, Shizuoka, Shizuoka Prefecture |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Currus Biologics | $7M | 29 Jun 2021 | Melbourne, Victoria, Australia | ||
Azura Ophthalmics | $20M | 22 Oct 2020 | Tel Aviv District | ||
Glyscend | $20M | 11 Jun 2020 | Baltimore, Maryland, United States | ||
Pathios Therapeutics | $8M | 18 Dec 2019 | England | ||
Denteric | $10M | 26 Sep 2019 | Victoria | ||
Azura Ophthalmics | $16M | 10 Oct 2017 | Tel Aviv District | ||
OncoRes Medical | $4M | 02 Jun 2017 | Western Australia | ||
Aravax | 01 Jan 2016 | Victoria | |||
Auspherix | $8M | 03 Jun 2015 | United Kingdom, England, United Kingdom |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Currus Biologics | $7M | 29 Jun 2021 | Melbourne, Victoria, Australia | ||
Azura Ophthalmics | $20M | 22 Oct 2020 | Tel Aviv District | ||
Glyscend | $20M | 11 Jun 2020 | Baltimore, Maryland, United States | ||
Pathios Therapeutics | $8M | 18 Dec 2019 | England | ||
Denteric | $10M | 26 Sep 2019 | Victoria | ||
Azura Ophthalmics | $16M | 10 Oct 2017 | Tel Aviv District | ||
OncoRes Medical | $4M | 02 Jun 2017 | Western Australia | ||
Aravax | 01 Jan 2016 | Victoria | |||
Auspherix | $8M | 03 Jun 2015 | United Kingdom, England, United Kingdom |
